[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519097":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":27,"responsibleParty":45,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Hamilton Health Sciences Corporation","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequential ICG and Technetium Detection",null,"ICG alone for the detection of SLN in early vulvar cancer",[13],"Procedure: ICG alone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","ICG alone","SLNs will be detected with ICG alone, labelled as such, and subsequent to that tested with Gamma probe for accuracy",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Andra Nica, MD","CONTACT","9053879495","64816","nica@hhsc.ca",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Hamilton Health Sciences","RECRUITING","Hamilton","Ontario","L8V5C2","Canada","CA",{"type":37,"coordinates":38},"Point",[39,40],-79.84963,43.25011,{"lat":40,"lon":39},[43],{"name":44,"role":23,"phone":10,"phoneExt":10,"email":10},"Andra Nica",{"type":46,"investigatorFullName":44,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Gynecologic Oncologist",[49],{"name":50,"class":6},"Juravinski Cancer Centre Foundation","100519097","indocyanine-green-for-detection-of-sentinel-lymph-nodes-in-comparison-to-icg-plus-technetium-in-the-evaluation-of-vulvar-squamous-cell-carcinoma-100519097",false,"NCT06039111","Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma","Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma: The IGNITE-V Study","IGNITE-V","Inclusion Criteria:\n\nAdult women (18 years of age) with FIGO Stage IB (\\> 1 mm depth of invasion) and small Stage II (4 cm) vulvar squamous cell carcinoma or cutaneous melanoma who are candidates for the Sentinel lymph node technique will be included (Negative clinical groin examination and\u002For imaging and primary unifocal vulvar tumor size of \\\u003C 4 cm).\n\nExclusion Criteria:\n\nWomen with a prior history of pelvic, vulvovaginal or inguinal radiation, with allergy or hypersensitivity to Technetium or ICG, or Bartholin gland cancer will be excluded.",true,"FEMALE","18 Years",{"count":63,"type":64},58,"ESTIMATED","OBSERVATIONAL","The aim of this study is to confirm prospectively if the use of near infrared-indocyanine green (NIR-ICG) alone offers similar accuracy and sensitivity to the gold standard dual technique for sentinel lymph node detection in early stage vulvar cancer.",[68],"Vulvar Cancer","2026-04-08",{"date":71,"type":72},"2026-04-13","ACTUAL",{"date":74,"type":72},"2023-10-01",{"date":76,"type":64},"2026-11-30",{"name":5,"class":6},1]